Problems of Social Hygiene, Public Health and History of MedicineProblems of Social Hygiene, Public Health and History of Medicine0869-866X2412-2106Joint-Stock Company Chicot101310.32687/0869-866X-2022-30-5-806-812Научная статьяEVALUATION OF THE MEDICAL AND ECONOMIC EFFICIENCY OF NON-INVASIVE PRENATAL TESTING IN MOSCOWGalaktionovaA. M.-KaplanovaM. T.kaplanova@evogenlab.ruBaranovaE. E.-SagaydakO. V.-OlenevA. S.-KharkchinovA. Yu.-ChernovaM. I.-YablonskiyK. P.-PatrushevM. A.-FilatovV. B.-NaygovzinaN. B.-Evogen LLC, MoscowRussian Medical Academy of Сontinuous Professional Education of Minzdrav of RussiaNational Medical Research Center of Cardiology of Minzdrav of RussiaMoscow City Health Department “Сity Clinical Hospital № 24”Russian Presidential Academy of National Economy and Public AdministrationANO “Moscow Centre for InnovativeHealthcare Technologies”A. I. Yevdokimov Moscow State University of Medicine and Dentistry”of Minzdrav of Russia1512202230580681229102022Copyright © 2022,2022Aim: to evaluate the medical and economic efficiency of prenatal diagnostics of fetal chromosomal abnormalities (CA) in pregnant women in Moscow using a non-invasive prenatal test (NIPT) as a second-line model.A comparative analysis of the medical and economic efficiency of standard prenatal screening and prenatal screening with NIPT in groups of pregnant women, registered in Moscow, with high and medium fetal CA risk was carried out. Analysis was based on the number of children born with CA and the costs of medical care (direct costs) and social payments (indirect costs), calculated for both scenarios.Following standard prenatal screening 111 children with CA would be born, following prenatal screening with NIPT - only 26. Including NIPT in prenatal diagnostics increases direct costs by 299.97 million rubles and reduces annual indirect costs from 61.19 to 28.95 million rubles. Starting from the 13th year of using NIPT the estimated effect of reducing indirect costs would exceed direct costs.NIPT in prenatal diagnostics can increase the detection of fetal CA and reduce indirect costs. Assessing the indirect costs in economic efficiency enhances the accuracy of the estimate.medical and economic efficiencyNIPTchromosomal abnormalitiesindirect costsdirect costsмедико-экономическая эффективностьнеинвазивный пренатальный тестхромосомные аномалиикосвенные затратыпрямые затратыПриказ Минздрава России от 20 октября 2020 № 1130н «Об утверждении Порядка оказания медицинской помощи по профилю.,акушерство и гинекология“». Режим доступа: https://roszdravnadzor.gov.ru/spec/medactivities/licensing/documents/748992Minear M. A., Lewis C., Pradhan S., Chandrasekharan S. Global perspectives on clinical adoption of NIPT. Prenat. Diagn. 2015 Sep 25;35(10):959-67. doi: 10.1002/pd.4637Guseh S. H. Noninvasive prenatal testing: from aneuploidy to single genes. Hum. Genet. 2019 Sep 25;139(9):1141-8. doi: 10.1007/s00439-019-02061-1Samura O. Update on noninvasive prenatal testing: A review based on current worldwide research. J. Obstet. Gynaecol. Res. 2020 Jun 17;46(8):1246-54. doi: 10.1111/jog.14268Liu Y., Liu H., He Y., Xu W., Ma Q., He Y. Clinical performance of non-invasive prenatal served as a first-tier screening test for trisomy 21, 18, 13 and sex chromosome aneuploidy in a pilot city in China. Hum. Genomics. 2020 Jun 5;14(1):21. doi: 10.1186/s40246-020-00268-2Oepkes D., Page-Christiaens G. C. (Lieve), Bax C. J., Bekker M. N., Bilardo C. M., Boon E. M. J., et al. Trial by Dutch laboratories for evaluation of non-invasive prenatal testing. Part I - clinical impact. Prenat. Diagn. 2016 Nov 15;36(12):1083-90. doi: 10.1002/pd.4945Gil M. M., Revello R., Poon L. C., Akolekar R., Nicolaides K. H. Clinical implementation of routine screening for fetal trisomies in the UKNHS: cell-free DNA test contingent on results from first-trimester combined test. Ultrasound Obstet. Gynecol. 2015 Oct 26;47(1):45-52. doi: 10.1002/uog.15783Zhang W., Mohammadi T., Sou J., Anis A. H. Cost-effectiveness of prenatal screening and diagnostic strategies for Down syndrome: A microsimulation modeling analysis. PLoS One. 2019 Dec 4;14(12):e0225281. doi: 10.1371/journal.pone.0225281Wang S., Liu K., Yang H., Ma J. A Cost-Effectiveness Analysis of Screening Strategies involving Noninvasive Prenatal Testing for Trisomy 21. Res. Square. 2020 Jan 14. doi: 10.21203/rs.2.20761/v1Емельяненко Е. С., Ветрова Н. В., Масюк С. В., Исаев А. А. Клиническая и экономическая эффективность методов пренатальной диагностики хромосомных аномалий. Доктор.Ру. Гинекология. Эндокринология. 2016;3(120):43-51.Nshimyumukiza L., Menon S., Hina H., Rousseau F., Reinharz D. Cell-free DNA noninvasive prenatal screening for aneuploidy versus conventional screening: A systematic review of economic evaluations. Clin. Genet. 2018 Jan 25;94(1):3-21. doi: 10.1111/cge.13155Приказ Департамента здравоохранения города Москвы от 13 марта 2020 г. № 199 «Об организации проведения неинвазивного пренатального теста в городе Москве». Режим доступа: https://www.mos.ru/dzdrav/documents/department-acts/view/237308220/Московский городской фонд обязательного медицинского страхования. Режим доступа: https://www.mgfoms.ru/medicinskie-organizacii/tarifi/2020Esbensen A. J. Health Conditions Associated with Aging and End of Life of Adults with Down Syndrome.Int Rev Res Ment Retard. 2010;39(C):107-126. doi: 10.1016/S0074-7750(10)39004-5Alshami A., Douedi S., Guida M., Ajam F., Desai D., Zales V., et al. Unusual Longevity of Edwards Syndrome: A Case Report. Genes. 2020 Dec 7;11(12):1466. doi: 10.3390/genes1112146615Peroos S., Forsythe E., Pugh J. H., Arthur-Farraj P., Hodes D. Longevity and Patau syndrome: what determines survival? BMJ. 2012 Dec 6;2012:bcr0620114381-bcr0620114381. doi: 10.1136/bcr-06-2011-4381Письмо Минэкономразвития России от 7 декабря 2018 № 36097-АТ/Д03 и «О доведении показателей долгосрочного прогноза социально-экономического развития Российской Федерации до 2036 года, используемых в целях ценообразования на продукцию, поставляемую по государственному оборонному заказу, на период с 2025 года». Режим доступа: https://www.economy.gov.ru/material/directions/makroec/prognozy_socialno_ekonomicheskogo_razvitiya/pismo_minekonomrazvitiya_rossii_ot_7_dekabrya_2018_g_36097_atd03i.htmlJohn N. M., Wright S. J., Gavan S. P., Vass C. M. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur. J. Health Econ. 2019 Jun 22;20(8):1123-31. doi: 10.1007/s10198-019-01082-xPrefumo F., Paolini D., Speranza G., Palmisano M., Dionisi M., Camurri L. The contingent use of cell-free fetal DNA for prenatal screening of trisomies 21, 18, 13 in pregnant women within a national health service: A budget impact analysis. PLoS One. 2019 Jun 12;14(6):e0218166. doi: 10.1371/journal.pone.0218166Neyt M., Hulstaert F., Gyselaers W.Introducing the non-invasive prenatal test for trisomy 21 in Belgium: a cost-consequences analysis. BMJ Open. 2014 Nov;4(11):e005922. doi: 10.1136/bmjopen-2014-005922Beulen L., Grutters J. P. C., Faas B. H., Feenstra I, van Vugt J. M. G., Bekker M. N. The consequences of implementing non-invasive prenatal testing in Dutch national health care: a cost-effectiveness analysis. Eur. J. Obstet. Gynecol. Reprod. Biol. 2014 Nov;182:53-61. doi: 10.1016/j.ejogrb.2014.08.02Nshimyumukiza L., Beaumont J. A., Rousseau F., Reinharz D.Introducing cell-free DNA noninvasive testing in a Down syndrome public health screening program: a budget impact analysis. Cost. Eff. Resour. Alloc. 2020 Nov 4;18(1):49. doi: 10.1186/s12962-020-00245-5